Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Emerywood Hematology Oncology
mi
from
High Point, NC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Emerywood Hematology Oncology
mi
from
High Point, NC
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Oncology Hematology Care, Inc.
mi
from
Cincinatti, OH
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Oncology Hematology Care, Inc.
mi
from
Cincinatti, OH
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Oncology Hematology Care, Inc.
mi
from
Wilmington, OH
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Oncology Hematology Care, Inc.
mi
from
Wilmington, OH
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Kaiser Permanente Northwest Region Oncology Hematology
mi
from
Portland, OR
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Kaiser Permanente Northwest Region Oncology Hematology
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
PinnacleHealth
mi
from
Camp Hill, PA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
PinnacleHealth
mi
from
Camp Hill, PA
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Pinnacle Health
mi
from
Harrisburg, PA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Pinnacle Health
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
University of Pittsburgh Medical Center - Cancer Centers
mi
from
Pittsburgh, PA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
University of Pittsburgh Medical Center - Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Center for Biomedical Research
mi
from
Knoxville, TN
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Center for Biomedical Research
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
UT Southwestern Medical Center
mi
from
Dallas, TX
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
San Antonio Military Medical Center
mi
from
Fort Sam Houston, TX
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
San Antonio Military Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Scott and White Memorial
mi
from
Temple, TX
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Scott and White Memorial
mi
from
Temple, TX
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
The Center for Cancer and Blood Disorders
mi
from
Weatherford, TX
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
The Center for Cancer and Blood Disorders
mi
from
Weatherford, TX
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Intermountain Healthcare
mi
from
St. George, UT
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Intermountain Healthcare
mi
from
St. George, UT
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Virginal Cancer Specialists, PC
mi
from
Fairfax, VA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Virginal Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Virginia Cancer Institute
mi
from
Midlothian, VA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Virginia Cancer Institute
mi
from
Midlothian, VA
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Virginia Cancer Institute
mi
from
Richmond, VA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated:  2/3/2014
University of Wisconsin
mi
from
Madison, WI
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Status: Enrolling
Updated: 2/3/2014
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study
Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study
Status: Enrolling
Updated:  2/12/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study
Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study
Status: Enrolling
Updated: 2/12/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI in Patients With Newly Diagnosed Ras Mutant Positive Metastatic Colorectal Cancer or Patients With Ras Mutant Positive Colorectal Cancer Who Have Just Completed a First Line Therapy With an Oxaliplatin or Irinotecan Plus Fluoropyrimidine and Bevacizumab Containing Regimen
Status: Enrolling
Updated:  2/12/2014
Georgetown University
mi
from
Washington,
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI in Patients With Newly Diagnosed Ras Mutant Positive Metastatic Colorectal Cancer or Patients With Ras Mutant Positive Colorectal Cancer Who Have Just Completed a First Line Therapy With an Oxaliplatin or Irinotecan Plus Fluoropyrimidine and Bevacizumab Containing Regimen
Status: Enrolling
Updated: 2/12/2014
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep
Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep
Status: Enrolling
Updated:  2/13/2014
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep
Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep
Status: Enrolling
Updated: 2/13/2014
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Radial Reload Laparoscopic Case Series
Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series
Status: Enrolling
Updated:  2/20/2014
University Hospitals of Cleveland
mi
from
Cleveland, OH
Radial Reload Laparoscopic Case Series
Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series
Status: Enrolling
Updated: 2/20/2014
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care
Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care
Status: Enrolling
Updated:  3/4/2014
Brigham and Women's Hosp
mi
from
Boston, MA
Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care
Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care
Status: Enrolling
Updated: 3/4/2014
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
New Individualized Therapy Trial for Metastatic Colorectal Cancer
A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay
Status: Enrolling
Updated:  3/11/2014
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
New Individualized Therapy Trial for Metastatic Colorectal Cancer
A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay
Status: Enrolling
Updated: 3/11/2014
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
New Individualized Therapy Trial for Metastatic Colorectal Cancer
A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay
Status: Enrolling
Updated:  3/11/2014
Inova Fairfax Hospital Department of Surgery
mi
from
Falls Church, VA
New Individualized Therapy Trial for Metastatic Colorectal Cancer
A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay
Status: Enrolling
Updated: 3/11/2014
Inova Fairfax Hospital Department of Surgery
mi
from
Falls Church, VA
Click here to add this to my saved trials
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated:  5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated: 5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
Status: Enrolling
Updated:  5/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
Status: Enrolling
Updated: 5/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue
Phase I Clinical Trial Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Malignant Colon Tissue
Status: Enrolling
Updated:  5/28/2014
James Graham Brown Cancer Center
mi
from
Louisville, KY
Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue
Phase I Clinical Trial Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Malignant Colon Tissue
Status: Enrolling
Updated: 5/28/2014
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer
Status: Enrolling
Updated:  6/20/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer
Status: Enrolling
Updated: 6/20/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
University of Southern California
mi
from
Los Angeles, CA
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
NorthShore University HealthSystem
mi
from
Evanston, IL
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
Northwestern Univeristy
mi
from
Evanston, IL
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
Northwestern Univeristy
mi
from
Evanston, IL
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
University of Indiana
mi
from
Indianapolis, IN
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
University of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
Boston Med Ctr
mi
from
Boston, MA
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/17/2014
Swedish Medical Center Cancer Institute
mi
from
Seattle, WA
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/17/2014
Swedish Medical Center Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Phase II Study of Second-line Irinotecan Plus Brivanib, a Dual Tyrosine Inhibitor of VEGFR and FGFR, in Metastatic Colorectal Cancer Patients Enriched for Elevated Levels of Plasma FGF Following Progression on Bevacizumab-based Treatment
Status: Enrolling
Updated:  1/7/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Phase II Study of Second-line Irinotecan Plus Brivanib, a Dual Tyrosine Inhibitor of VEGFR and FGFR, in Metastatic Colorectal Cancer Patients Enriched for Elevated Levels of Plasma FGF Following Progression on Bevacizumab-based Treatment
Status: Enrolling
Updated: 1/7/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102
Status: Enrolling
Updated:  5/14/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102
Status: Enrolling
Updated: 5/14/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102
Status: Enrolling
Updated:  5/14/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102
Status: Enrolling
Updated: 5/14/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials